

Iron-Mediated Direct Arylation with Arylboronic Acids through an Aryl Radical Transfer Pathway

Jian Wang, Shan Wang, Gao Wang, Ji Zhang* and Xiao-Qi Yu*

Department of Chemistry, Key Laboratory of Green Chemistry and Technology (Ministry of Education), Sichuan University, Chengdu, 610064, P. R. China

State Key Laboratory of Biotherapy, Sichuan University, Chengdu, Sichuan 610041, P. R. China

Fax: +86 28 85415886; E-mail: xqyu@scu.edu.cn

1: General information	S2
2: Optimization studies of direct arylation of pyridines	S2
3: Optimization studies of direct arylation of quinones	S2
4: Investigation of radical scavenger effect	S3
5: General procedure for arylation of quinones with arylboronic acids (I)...	S4
6: General procedure for arylation of pyridines with arylboronic acids (II).....	S8
7: Copies of product ¹ H NMR and ¹³ C NMR	S16


General information:

All reagents were purchased from commercial suppliers and used without further purification. ¹H-NMR, ¹³C-NMR spectra were measured on a Bruker AM400 NMR spectrometer (400 MHz or 100MHz, respectively) with CDCl₃ as solvent and recorded in ppm relative to internal tetramethylsilane standard. Mass spectroscopy data of the product was collected on an Agilent 6890-5973N GCMS-EI instrument.

Optimization studies of direct arylation of pyridines

For initial optimization of the reaction conditions, we selected 4-cyanopyridine (**4a**) and benzeneboronic acid (**2a**) as model substrates, and the results are summarized in Table S1.

Table S1: Optimization of direct arylation of pyridines




Entry ^a	[Fe] (equiv)	Oxidant (equiv)	Additive (equiv)	Yield(%) ^b
1	FeS(1.0)	K ₂ S ₂ O ₈ (3.0)	none	55.9
2	Fe ₂ (SO ₄) ₃ (1.0)	K ₂ S ₂ O ₈ (3.0)	none	42.7
3	Fe ₂ O ₃ (1.0)	K ₂ S ₂ O ₈ (3.0)	none	13.7
4	Fe ₃ O ₄ (1.0)	K ₂ S ₂ O ₈ (3.0)	none	24.3
5	FeCl ₃ • 6H ₂ O(1.0)	K ₂ S ₂ O ₈ (3.0)	none	11.9
6	FeCl ₂ • 4H ₂ O(1.0)	K ₂ S ₂ O ₈ (3.0)	none	trace
7 ^[c]	Fe(C ₂ O ₄) • 4H ₂ O (1.0)	K ₂ S ₂ O ₈ (3.0)	none	68.2
8 ^[c,d]	Fe(C ₂ O ₄) • 4H ₂ O (1.0)	K ₂ S ₂ O ₈ (3.0)	none	56.3
9 ^[c,d]	Fe(C ₂ O ₄) • 4H ₂ O (1.0)	K ₂ S ₂ O ₈ (3.0)	TFA(1.0)	57.0
10	FeS(1.0)	K₂S₂O₈(3.0)	TFA(1.0)	68.6
11	FeS(1.0)	K ₂ S ₂ O ₈ (3.0)	(COOH) ₂ (1.0)	47.6
12	FeS(1.0)	K ₂ S ₂ O ₈ (3.0)	H ₂ SO ₄ (1.0)	58.6
13	FeS(1.0)	K ₂ S ₂ O ₈ (3.0)	HCl(1.0)	26.7
14	FeS (1.0)	K ₂ S ₂ O ₈ (3.0)	(CH ₃) ₃ CCO ₂ H(1.0)	30.8
15	FeS (1.0)	K ₂ S ₂ O ₈ (3.0)	Mn(OAc) ₃ (1.0)	0
16	FeS (1.0)	Oxone(3.0)	none	0

^a Reaction conditions: **4a**(0.5 mmol), **2a** (1.5 equiv), 4 mL of solvent (1:1, v/v), 25 °C, 40 h. ^b Yield of isolated of 2-arylation product. ^c Ultrapure iron salt (99.999%). ^d 20h.

Optimization studies of direct arylation of quinones

For initial optimization of the reaction conditions, we selected 1,4-benzoquinone (**1a**) and benzeneboronic acid (**2a**) as model substrates, and the results are summarized in Table S2.

Table S2: Optimization of direct arylation of quinones



Entry ^a	[Fe] (equiv)	Oxidant (equiv)	Solvent	Yield(%) ^b
1 ^c	Fe ₂ (SO ₄) ₃ (1.0)	K ₂ S ₂ O ₈ (3.0)	CH ₂ Cl ₂ /H ₂ O	57.6
2	Fe ₂ (SO ₄) ₃ (1.0)	K ₂ S ₂ O ₈ (3.0)	Acetone/H ₂ O	5.54
3	Fe ₂ (SO ₄) ₃ (1.0)	K ₂ S ₂ O ₈ (3.0)	EtOAc/H ₂ O	45.9
4	Fe ₂ (SO ₄) ₃ (1.0)	K ₂ S ₂ O ₈ (3.0)	H ₂ O	trace
5	Fe ₂ (SO ₄) ₃ (1.0)	K ₂ S ₂ O ₈ (3.0)	CH ₂ Cl ₂	0
6	none	K ₂ S ₂ O ₈ (3.0)	CH ₂ Cl ₂ /H ₂ O	trace
7 ^d	FeCl ₃ (1.0)	K ₂ S ₂ O ₈ (3.0)	CH ₂ Cl ₂ /H ₂ O	trace
8 ^d	FeCl ₃ ·6H ₂ O(1.0)	K ₂ S ₂ O ₈ (3.0)	CH ₂ Cl ₂ /H ₂ O	trace
9 ^d	FeSO ₄ ·7H ₂ O(1.0)	K ₂ S ₂ O ₈ (3.0)	CH ₂ Cl ₂ /H ₂ O	55.5
10 ^d	Fe(acac) ₃ (1.0)	K ₂ S ₂ O ₈ (3.0)	CH ₂ Cl ₂ /H ₂ O	27.5
11	Fe ₃ O ₄ (1.0)	K ₂ S ₂ O ₈ (3.0)	CH ₂ Cl ₂ /H ₂ O	17.6
12	FeS(1.0)	K ₂ S ₂ O ₈ (3.0)	CH ₂ Cl ₂ /H ₂ O	83.9
13	FeS(0.5)	K₂S₂O₈ (3.0)	CH₂Cl₂/H₂O	81.5
14	FeS (0.25)	K ₂ S ₂ O ₈ (3.0)	CH ₂ Cl ₂ /H ₂ O	63.2
15 ^e	FeS (0.5)	K ₂ S ₂ O ₈ (2.0)	CH ₂ Cl ₂ /H ₂ O	71.6
16 ^e	FeS (0.5)	K ₂ S ₂ O ₈ (1.0)	CH ₂ Cl ₂ /H ₂ O	45.8
17 ^e	FeS (0.5)	Oxone(2.0)	CH ₂ Cl ₂ /H ₂ O	0
18 ^e	FeS (0.5)	H ₂ O ₂ (2.0)	CH ₂ Cl ₂ /H ₂ O	0
19 ^e	FeS (0.5)	TBHP(2.0)	CH ₂ Cl ₂ /H ₂ O	0
20 ^e	FeS (0.5)	DTBP(2.0)	CH ₂ Cl ₂ /H ₂ O	0
21	FeS (1.0)	none	CH ₂ Cl ₂ /H ₂ O	0

^a Reaction conditions (unless otherwise stated): **1a** (0.5 mmol), **2a** (1.5 equiv), 4 mL of solvent (1:1, v/v), 25°C, 24 h. ^b Yield of isolated. ^c 36 h. ^d 60 h. ^e 12 h.

Investigation of radical scavenger effect

Different equivalent amounts of TEMPO were mixed into reaction systems about the direct arylation of 1, 4-benzoquinone or 4-cyanopyridine with benzenboronic acid, and the results are summarized in Table S3. Radical scavenger reduced the yield obviously.

Table S3: Investigation of radical scavenger effect

Entry	C-H Sources	TEMPO (equiv) ^[a]	General procedure	Yield(%)	Yield(%) ^[b]
1	1, 4-benzoquinone or 4-cyanopyridine	1.0	I or II	22.6 or 27.7	81.5 or 90.3
2	1, 4-benzoquinone or 4-cyanopyridine	1.5	I or II	21.4 or 21.3	81.5 or 90.3


	4-cyanopyridine				
3	1, 4-benzoquinone or 2.0	I or II	21.3 or trace	81.5 or 90.3	
	4-cyanopyridine				

[a] TEMPO = 2,2,6,6-Tetramethyl-1-piperidinyloxy. [b] No TEMPO was mixed.

General procedure for arylation of quinones with arylboronic acids (I)


To a test tube equipped with magnetic stir bar was charged with quinone derivative (0.5 mmol, 1.0 equiv), FeS (0.25 mmol, 0.5 equiv), arylboronic acids (0.75 mmol, 1.5 equiv), $K_2S_2O_8$ (1.5 mmol, 3.0 equiv) in solvent (4 mL, 1:1 DCM:H₂O). The test tube was sealed with rubber septum, and stirred for 24 h at room temperature. The resulting solution was directly filtered through a pad of celite and washed with dichloromethane (15 mL). The filtrate was washed with a saturated solution of NaHCO₃ (3 x 15 mL) and the aqueous layer was extracted again with dichloromethane (3 x 15 mL). The combined organic layer was concentrated under reduced pressure after had been dried over Na₂SO₄. The crude product was purified by column chromatography using the indicated eluent. The identity and purity of the known product was confirmed by GC-MC, ¹H-NMR and ¹³C-NMR.

2-Phenyl-1, 4-benzoquinone (3a).




EtOAc/*n*-hexane (1:10); yellow solid (75.1mg, 81.5%); ¹H NMR (400 MHz, CDCl₃) δ=7.47 (br, 5H), 6.89-6.83 (m, 3H); ¹³C NMR (100 MHz, CDCl₃) δ=187.5, 186.6, 145.9, 137.1, 136.3, 132.7, 130.1, 129.2, 128.6; MS (EI) *m/z* (%) 184 (M⁺,100), 156 (50), 128 (38), 102(32), 82(38).

2-(4-Methylphenyl)-1, 4-benzoquinone (3b).



EtOAc/*n*-hexane (1:10); yellow solid (90.3mg, 91.1%); ¹H NMR (400 MHz, CDCl₃) δ=7.39 (d, *J* = 8.0 Hz, 2H), 7.26 (d, *J* = 8.0 Hz, 2H), 6.87-6.80 (m, 3H), 2.40 (s, 3H); ¹³C NMR (100 MHz, CDCl₃) δ=187.7, 186.9, 145.9, 140.6, 137.1, 136.2, 132.0, 129.8, 129.3, 129.2, 21.4; MS (EI) *m/z* (%) 198 (M⁺,100), 183 (30), 170 (72), 155(20), 141(55), 115(78), 82(64).


2-(3-Methylphenyl)-1, 4-benzoquinone (3c).



EtOAc/*n*-hexane (1:10); yellow solid (95.7mg, 96.6%); ¹H NMR (400 MHz, CDCl₃)


δ =7.36-7.26 (m, 4H), 6.88-6.82 (m, 3H), 2.41 (s, 3H); ^{13}C NMR (100 MHz, CDCl_3) δ =187.7, 186.7, 146.2, 138.3, 137.1, 136.2, 132.6, 131.0, 129.8, 128.5, 126.4, 21.4; MS (EI) m/z (%) 198 (M^+ ,100), 183 (30), 170 (72), 155(25), 141(68), 115(72), 82(60).

2-(2-Methylphenyl)-1, 4-benzoquinone (3d).




EtOAc/*n*-hexane (1:10); yellow oil (95.8mg, 96.7%); ^1H NMR (400 MHz, CDCl_3) δ =7.25 (t, J = 7.4 Hz, 1H), 7.18-7.14 (m, 2H), 7.01 (d, J = 7.6 Hz, 1H), 6.80-6.74 (m, 2H), 6.63 (d, J = 2.2 Hz, 1H), 2.10 (s, 3H); ^{13}C NMR (100 MHz, CDCl_3) δ =186.6, 185.2, 147.4, 135.8, 135.3, 135.1, 133.5, 132.0, 129.4, 128.5, 128.2, 124.8, 19.3; MS (EI) m/z (%) 198 (M^+ ,100), 181 (10), 170 (51), 153(12), 141(43), 115(60).

2-(4-Methoxyphenyl)-1, 4-benzoquinone (3e).




EtOAc/*n*-hexane (1:10); red solid (40.6mg, 37.9%); ^1H NMR (400 MHz, CDCl_3) δ =7.48 (d, J = 8.8 Hz, 2H), 6.97 (d, J = 8.8 Hz, 2H), 6.86-6.79 (m, 3H), 3.86 (s, 3H); ^{13}C NMR (100 MHz, CDCl_3) δ =187.7, 187.1, 161.4, 145.2, 137.0, 136.3, 131.1, 130.9, 125.0, 114.2, 55.4; MS (EI) m/z (%) 214 (M^+ ,100), 186 (20), 132 (58), 115(20), 89(20).

2-(4-*tert*-Butylphenyl)-1, 4-benzoquinone (3f).



EtOAc/*n*-hexane (1:10); yellow solid (110.7mg, 92.1%); ^1H NMR (400 MHz, CDCl_3) δ =7.47 (d, J = 8.0 Hz, 2H), 7.43 (d, J = 8.4 Hz, 2H), 6.88-6.81 (m, 3H), 1.35 (s, 9H); ^{13}C NMR (100 MHz, CDCl_3) δ =187.7, 186.9, 153.7, 145.8, 137.1, 136.3, 132.1, 129.8, 127.4, 125.6, 34.9, 31.2; MS (EI) m/z (%) 240 (M^+ ,5), 225 (95), 197 (27), 184(100).


2-(4-Fluorophenyl)-1, 4-benzoquinone (3g).



EtOAc/*n*-hexane (1:10); yellow solid (68.1mg, 67.4%); ^1H NMR (400 MHz, CDCl_3) δ =7.51-7.48 (m, 2H), 7.17-7.13 (m, 2H), 6.89-6.83 (m, 3H); ^{13}C NMR (100 MHz, CDCl_3) δ =187.4, 186.6, 165.2, 144.8, 137.0, 136.4, 132.5, 131.3 (d, J = 8.3Hz), 129.5, 115.8 (d, J =


21.8 Hz); MS (EI) m/z (%) 202 (M^+ ,100), 174 (52), 146 (43), 120(42), 82(57).

2-(4-Bromophenyl)-1, 4-benzoquinone (3h).




EtOAc/*n*-hexane (1:10); yellow solid (127.7mg, 97.1%); ^1H NMR (400 MHz, CDCl_3) δ = 7.59 (d, J = 8.3 Hz, 2H), 7.37 (d, J = 8.4 Hz, 2H), 6.90-6.83 (m, 3H); ^{13}C NMR (100 MHz, CDCl_3) δ =187.3, 186.3, 144.9, 137.0, 136.4, 132.7, 131.9, 131.5, 130.8, 125.0; MS (EI) m/z (%) 263 (M^+ ,12), 183 (100), 155(30), 127(20), 101(22), 82(27).

2-(4-Chlorophenyl)-1, 4-benzoquinone (3i).




EtOAc/*n*-hexane (1:10); yellow solid (92.8mg, 84.9%); ^1H NMR (400 MHz, CDCl_3) δ =7.44(brs, 4H), 6.90-6.83 (m, 3H); ^{13}C NMR (100 MHz, CDCl_3) δ =187.4, 186.4, 144.8, 137.0, 136.6, 136.4, 132.7, 131.0, 130.6, 128.9; MS (EI) m/z (%) 218 (M^+ ,41), 183 (100), 155 (57), 136(48), 127(32), 101(29), 82(65).

2-(3-Chlorophenyl)-1, 4-benzoquinone (3j).




EtOAc/*n*-hexane (1:10); pale yellow solid (97.6mg, 89.3%); ^1H NMR (400 MHz, CDCl_3) δ =7.48(s, 1H), 7.45 (d, J = 7.6 Hz, 1H), 7.40 (d, J = 7.6 Hz, 1H), 7.37 (t, J = 4.4 Hz, 1H), 6.90-6.84 (m, 3H); ^{13}C NMR (100 MHz, CDCl_3) δ =187.3, 186.1, 144.6, 137.0, 136.4, 134.6, 134.3, 133.2, 130.2, 129.8, 129.3, 127.4; MS (EI) m/z (%) 218 (M^+ ,30), 183 (100), 155 (62), 136(39), 127(30), 101(25), 82(54).

2-(2-Chlorophenyl)-1, 4-benzoquinone (3k).




EtOAc/*n*-hexane (1:10); yellow oil (93.6mg, 85.6%); ^1H NMR (400 MHz, CDCl_3) δ =7.46(d, J = 7.9 Hz, 1H), 7.41-7.32 (m, 2H), 7.24-7.21 (m, 1H), 6.92-6.85 (m, 2H), 6.80 (s, 1H); ^{13}C NMR (100 MHz, CDCl_3) δ =187.2, 185.1, 146.1, 136.8, 136.5 (d, J = 11.8 Hz), 135.0, 133.1, 132.4, 130.8, 130.7, 129.8, 126.8; MS (EI) m/z (%) 218 (M^+ ,27), 183 (100), 155 (78), 136(47), 127(38), 101(35), 82(64).

2- (naphthalen-2-yl) -1,4-benzoquinone (3l).




EtOAc/*n*-hexane (1:20); yellow solid (35.7mg, 30.5%); ^1H NMR (400 MHz, CDCl_3) δ =8.05(s, 1H), 7.94-7.86 (m, 3H), 7.58-7.52 (m, 3H), 7.0 (d, J = 2.1 Hz, 1H), 6.93-6.85 (m, 2H); ^{13}C NMR (100 MHz, CDCl_3) δ =187.6, 186.9, 145.9, 137.1, 136.3, 133.9, 132.9(2C), 130.1, 129.8, 128.8, 128.3, 127.7, 127.5, 126.7, 125.9; MS (EI) m/z (%) 234 (M^+ ,100), 206 (39), 178 (30), 152(80).

2,6-Dimethyl-3-phenyl-1,4-benzoquinone (3n).




EtOAc/*n*-hexane (1:20); yellow solid (80.2mg, 75.6%); ^1H NMR (400 MHz, CDCl_3) δ =7.45-7.39(m, 3H), 7.16 (d, J = 2.0Hz, 1H), 7.14 (d, J = 1.2Hz, 1H), 6.66 (d, J = 1.0 Hz, 1H), 2.11 (d, J = 1.4 Hz, 3H), 1.97 (s, 3H); ^{13}C NMR (100 MHz, CDCl_3) δ =188.6, 186.8, 145.6, 143.7, 141.6, 133.2, 132.9, 129.5, 128.5, 128.1, 16.0, 14.1; MS (EI) m/z (%) 212 (M^+ ,100), 197 (37), 183 (16), 169(42), 141(15), 115(32).

2,6-Dimethoxy-3-(4-methylphenyl)-1,4-benzoquinone (3o).




EtOAc/*n*-hexane (1:10); orange solid (105.7mg, 86.6%); ^1H NMR (400 MHz, CDCl_3) δ =7.44-7.39 (m, 3H), 7.32-7.28 (m, 2H), 5.96(s, 1H), 3.85 (s, 3H), 3.74 (s, 3H); ^{13}C NMR (100 MHz, CDCl_3) δ =186.7, 178.6, 157.3, 153.9, 130.6, 130.1, 129.2, 128.8, 127.9, 107.2, 61.3, 56.5; MS (EI) m/z (%) 244 (M^+ ,100), 226 (85), 201(94), 145(93), 183 (47).

2,3-Dimethoxy-5-methyl-6-phenyl-1,4-benzoquinone (3q).




EtOAc/*n*-hexane (1:10); orange oil (42.6mg, 33.0%); ^1H NMR (400 MHz, CDCl_3) δ =7.45-7.39 (m, 3H), 7.16-7.13 (m, 2H), 4.06 (s, 3H), 4.02 (s, 3H), 3.99 (s, 3H); ^{13}C NMR (100 MHz, CDCl_3) δ =184.8, 183.6, 144.9, 144.1, 141.8, 139.9, 131.3, 129.5, 128.6, 128.1, 61.3, 61.2, 13.8; MS (EI) m/z (%) 258 (M^+ ,100), 213 (66), 187 (30), 159(62), 115(57).

2,5-Dichloro-3-phenyl-1,4-benzoquinone (3r).



EtOAc/*n*-hexane (1:10); orange solid (73.7mg, 58.2%); ¹H NMR (400 MHz, CDCl₃) δ=7.49-7.47 (m, 3H), 7.30-7.27 (m, 2H), 7.24 (s, 1H); ¹³C NMR (100 MHz, CDCl₃) δ=177.6, 177.2, 144.7, 144.5, 143.7, 133.0, 130.7, 129.9, 129.6, 128.3; MS (EI) *m/z* (%) 252 (M⁺, 74), 217 (100), 189 (89), 161(25), 136(23), 126(34).

2-phenyl-1,4-naphthoquinone (3s).




EtOAc/*n*-hexane (1:10); yellow solid (12.9mg, 11.0%); ¹H NMR (400 MHz, CDCl₃) δ=8.21-8.18 (m, 1H), 8.14-8.12 (m, 1H), 7.80-7.78 (m, 2H), 7.59-7.57 (m, 2H), 7.49-7.47 (m, 3H), 7.09 (s, 1H); ¹³C NMR (100 MHz, CDCl₃) δ=185.2, 184.4, 148.2, 135.3, 133.9, 133.8, 133.4, 132.5, 132.1, 130.0, 129.4, 128.5, 127.1, 126.0; MS (EI) *m/z* (%) 234 (M⁺, 100), 206 (65), 178 (24), 104(30), 76(25).

General procedure for arylation of pyridines with arylboronic acids (II)

To a test tube equipped with magnetic stir bar was charged with pyridine derivative (0.5 mmol, 1.0 equiv), TFA(1.0 equiv), FeS (0.5 mmol, 1.0 equiv), arylboronic acids (0.75 mmol, 1.5 equiv), K₂S₂O₈ (1.5 mmol, 3.0 equiv) in solvent (4 mL, 1:1 DCM:H₂O). The test tube was sealed with rubber septum, and stirred for 40 h at room temperature. The resulting solution was directly filtered through a pad of celite and washed with dichloromethane (15 mL). The filtrate was washed with a saturated solution of NaHCO₃ (3 x 15 mL) and the aqueous layer was extracted again with dichloromethane (3 x 15 mL). The combined organic layer was concentrated under reduced pressure after had been dried over Na₂SO₄. The crude product was purified by column chromatography using the indicated eluent. The identity and purity of the known product was confirmed by GC-MC, ¹H-NMR and ¹³C-NMR.


2-phenylisonicotinonitrile (5a-C2), 3-phenylisonicotinonitrile (5a-C3).



EtOAc/*n*-hexane (1:10); C2: pale yellow solid (68.6mg, 76.1%); ¹H NMR (400 MHz, CDCl₃) δ=8.86 (dd, *J* = 4.8, 0.6 Hz, 1H), 8.01 (d, *J* = 1.9 Hz, 1H), 7.99 (d, *J* = 1.4 Hz, 1H), 7.95 (s, 1H), 7.51 (d, *J* = 5.6 Hz, 1H), 7.50 (s, 2H), 7.45 (dd, *J* = 5.0, 1.4 Hz, 1H); ¹³C NMR (100 MHz, CDCl₃) δ=158.8, 150.6, 137.3, 130.2, 129.1, 127.0, 123.2, 122.1, 121.2, 116.7; MS (EI) *m/z* (%) 180 (M⁺, 100), 153 (16), 126 (10); C3: pale yellow solid (12.8mg, 14.2%); ¹H NMR (400 MHz, CDCl₃) δ=8.86(s, 1H), 8.75 (d, *J* = 5.0 Hz, 1H), 7.63 (d, *J* = 5.0 Hz, 1H),


7.60-7.52 (m, 5H); ^{13}C NMR (100 MHz, CDCl_3) δ =151.0, 148.7, 135.1, 134.4, 129.6, 129.2, 128.8, 126.1, 118.9, 116.3; MS (EI) m/z (%) 180 (M^+ , 100), 153 (28), 126 (10).

2-(*o*-tolyl)isonicotinonitrile (5b-C2), 3-(*o*-tolyl)isonicotinonitrile (5b-C3).




EtOAc/*n*-hexane (1:10); C2: pale yellow solid (72.4mg, 74.6%); ^1H NMR (400 MHz, CDCl_3) δ =8.87 (t, J = 4.5 Hz, 1H), 7.64 (d, J = 0.9 Hz, 1H), 7.48 (dd, J = 5.0, 1.4 Hz, 1H), 7.40-7.30 (m, 4H), 2.38 (s, 3H); ^{13}C NMR (100 MHz, CDCl_3) δ =161.5, 150.2, 138.4, 135.9, 131.2, 129.6, 129.3, 126.2, 125.6, 122.9, 120.7, 116.7, 20.3; MS (EI) m/z (%) 194 (M^+ , 100), 167 (40), 139 (12); C3: light yellow oil (16.1mg, 16.6%); ^1H NMR (400 MHz, CDCl_3) δ =8.80 (d, J = 5.0 Hz, 1H), 8.76 (s, 1H), 7.65 (d, J = 5.0 Hz, 1H), 7.45-7.33 (m, 3H), 7.24 (d, J = 7.4 Hz, 1H), 2.25 (s, 3H); ^{13}C NMR (100 MHz, CDCl_3) δ =151.5, 148.9, 139.3, 136.1, 134.2, 130.8, 129.8, 129.6, 126.2, 125.3, 120.6, 115.8, 19.9; MS (EI) m/z (%) 194 (M^+ , 100), 166 (12).

2-(*m*-tolyl)isonicotinonitrile (5c-C2), 3-(*m*-tolyl)isonicotinonitrile (5c-C3).




EtOAc/*n*-hexane (1:10); C2: pale yellow solid (67.8mg, 69.8%); ^1H NMR (400 MHz, CDCl_3) δ =8.85 (d, J = 4.8 Hz, 1H), 7.94 (s, 1H), 7.83 (s, 1H), 7.77 (d, J = 7.6 Hz, 1H), 7.45-7.39 (m, 2H), 7.31 (d, J = 7.5 Hz, 1H), 2.46 (s, 3H); ^{13}C NMR (100 MHz, CDCl_3) δ =159.0, 150.6, 138.9, 137.3, 131.0, 129.0, 127.7, 124.1, 123.1, 122.1, 121.1, 116.8, 21.5; MS (EI) m/z (%) 194 (M^+ , 100), 167 (21), 139 (10); C3: pale yellow solid (22.6mg, 23.3%); ^1H NMR (400 MHz, CDCl_3) δ =8.85 (s, 1H), 8.74 (d, J = 5.0 Hz, 1H), 7.61 (d, J = 5.0 Hz, 1H), 7.43 (t, J = 7.8 Hz, 1H), 7.38 (d, J = 2.1 Hz, 2H), 7.33 (d, J = 7.5 Hz, 1H), 2.46 (s, 3H); ^{13}C NMR (100 MHz, CDCl_3) δ =151.0, 148.6, 139.0, 138.9, 134.4, 130.3, 129.4, 129.0, 126.0, 125.9, 118.8, 116.4, 21.5; MS (EI) m/z (%) 194 (M^+ , 100), 179 (12), 166 (10).

2-(*p*-tolyl)isonicotinonitrile (5d-C2), 3-(*p*-tolyl)isonicotinonitrile (5d-C3).




EtOAc/*n*-hexane (1:10); C2: pale yellow solid (61.1mg, 62.9%); ^1H NMR (400 MHz, CDCl_3) δ =8.83 (d, J = 5.0 Hz, 1H), 7.91 (d, J = 3.4 Hz, 2H), 7.89 (s, 1H), 7.41 (d, J = 4.9 Hz, 1H), 7.32 (d, J = 8.1 Hz, 2H), 2.43 (s, 3H); ^{13}C NMR (100 MHz, CDCl_3) δ =158.8, 150.6, 140.5, 134.6, 129.8, 126.9, 122.8, 121.7, 121.1, 116.8, 21.4; MS (EI) m/z (%) 194 (M^+ , 100), 167 (15), 140 (10); C3: pale yellow solid (21.9mg, 22.6%); ^1H NMR (400 MHz, CDCl_3) δ =8.85 (s, 1H), 8.72 (d, J = 5.0 Hz, 1H), 7.61 (d, J = 5.0 Hz, 1H), 7.49 (d, J = 8.2 Hz, 2H), 7.35 (d, J = 7.9 Hz, 2H), 2.45 (s, 3H); ^{13}C NMR (100 MHz, CDCl_3) δ =151.0, 148.4, 139.8, 138.8, 131.5, 129.9, 128.7, 126.0, 118.7, 116.5, 21.3; MS (EI) m/z (%) 194 (M^+ , 100), 179 (10), 166 (10).

2-(4-methoxyphenyl)isonicotinonitrile (5e-C2), 3-(4-methoxyphenyl)isonicotinonitrile (5e-C3).




EtOAc/*n*-hexane (1:10); C2: pale yellow solid (54.4mg, 51.8%); ^1H NMR (400 MHz, CDCl_3) δ =8.81 (t, J = 2.4 Hz, 1H), 7.97 (d, J = 8.9 Hz, 2H), 7.88 (s, 1H), 7.37 (dd, J = 5.0, 1.3 Hz, 1H), 7.02 (d, J = 8.8 Hz, 2H), 3.88 (s, 3H); ^{13}C NMR (100 MHz, CDCl_3) δ =161.4, 158.4, 150.5, 129.9, 128.4, 122.3, 121.3, 121.1, 116.9, 55.4; MS (EI) m/z (%) 210 (M^+ , 100), 195 (17), 167 (26), 140 (21); C3: pale yellow solid (29.3mg, 27.9%); ^1H NMR (400 MHz, CDCl_3) δ =8.84(s, 1H), 8.70 (d, J = 5.0 Hz, 1H), 7.60 (d, J = 5.0 Hz, 1H), 7.54 (d, J = 8.8 Hz, 2H), 7.07 (d, J = 8.8 Hz, 2H), 3.89 (s, 3H); ^{13}C NMR (100 MHz, CDCl_3) δ =160.7, 150.9, 148.1, 138.5, 130.1, 126.7, 126.0, 118.4, 116.6, 114.7, 55.4; MS (EI) m/z (%) 210 (M^+ , 100), 195 (23), 167 (36), 140 (10).

2-(4-*tert*-butylphenyl)isonicotinonitrile (5f-C2), 3-(4-*tert*-butylphenyl)isonicotinonitrile (5f-C3).




EtOAc/*n*-hexane (1:10); C2: pale yellow solid (85.1mg, 72.0%); ^1H NMR (400 MHz, CDCl_3) δ =8.84 (d, J = 5.0 Hz, 1H), 7.95 (s, 1H), 7.93 (s, 2H), 7.53 (d, J = 8.5 Hz, 2H), 7.41 (dd, J = 5.0, 1.3 Hz, 1H), 1.37 (s, 9H); ^{13}C NMR (100 MHz, CDCl_3) δ =158.7, 153.7, 150.6, 134.5, 126.7, 126.1, 122.8, 121.8, 121.1, 116.9, 34.8, 31.2; MS (EI) m/z (%) 236 (M^+ , 24), 221 (100), 193 (19), 181 (15); C3: light yellow oil (29.8mg, 25.2%); ^1H NMR (400 MHz, CDCl_3) δ =8.87(s, 1H), 8.72 (d, J = 5.0 Hz, 1H), 7.61 (d, J = 5.0 Hz, 1H), 7.58-7.53 (m, 4H), 1.38 (s, 9H); ^{13}C NMR (100 MHz, CDCl_3) δ =152.8, 151.0, 148.4, 138.6, 131.5, 128.5, 126.2, 126.1, 118.6, 116.6, 34.8, 31.2; MS (EI) m/z (%) 236 (M^+ , 29), 221 (100), 205 (13), 193 (26).

2-(4-fluorophenyl)isonicotinonitrile (5g-C2), 3-(4-fluorophenyl)isonicotinonitrile (5g-C3).




EtOAc/*n*-hexane (1:10); C2: white solid (38.5mg, 38.8%); ^1H NMR (400 MHz, CDCl_3) δ =8.84 (dd, J = 5.0, 0.7 Hz, 1H), 8.02-7.99 (m, 2H), 7.90 (d, J = 0.9 Hz, 1H), 7.45 (dd, J = 5.0, 1.4 Hz, 1H), 7.23-7.17 (m, 2H); ^{13}C NMR (100 MHz, CDCl_3) δ =157.7, 150.7, 133.5, 129.0 (d, J = 8.6 Hz), 123.1, 121.7, 121.3, 116.6, 116.3, 116.0; MS (EI) m/z (%) 198 (M^+ , 100), 171 (14), 145 (10); C3: pale yellow solid (37.0mg, 37.3%); ^1H NMR (400 MHz, CDCl_3) δ =8.84(s, 1H), 8.76 (d, J = 5.0 Hz, 1H), 7.63 (d, J = 5.0 Hz, 1H), 7.59-7.56 (m, 2H), 7.27-7.23 (m, 2H); ^{13}C NMR (100 MHz, CDCl_3) δ =162.4, 150.8, 148.9, 137.7, 130.8, 130.7, 126.0, 118.9, 116.5, 116.3; MS (EI) m/z (%) 198 (M^+ , 100), 171 (30).

2-(4-bromophenyl)isonicotinonitrile (5h-C2), 3-(4-bromophenyl)isonicotinonitrile (5h-C3).




EtOAc/*n*-hexane (1:10); C2: pale yellow solid (19.5mg, 15.1%); ^1H NMR (400 MHz, CDCl_3) δ =8.86 (dd, J = 5.0, 0.6 Hz, 1H), 7.92 (s, 1H), 7.89 (d, J = 8.6 Hz, 2H), 7.65 (d, J = 8.6 Hz, 2H), 7.47 (dd, J = 5.0, 1.3 Hz, 1H); ^{13}C NMR (100 MHz, CDCl_3) δ =157.6, 150.8, 136.2, 132.3, 128.5, 125.0, 123.5, 121.8, 121.4, 116.5; MS (EI) m/z (%) 258 (M^+ , 100), 179 (75), 152 (44), 125 (14); C3: pale yellow solid (33.5mg, 25.9%); ^1H NMR (400 MHz, CDCl_3) δ =8.77 (s, 1H), 8.70 (d, J = 5.0 Hz, 1H), 7.62 (d, J = 8.4 Hz, 2H), 7.56 (d, J = 5.0 Hz, 1H), 7.39 (d, J = 8.4 Hz, 2H); ^{13}C NMR (100 MHz, CDCl_3) δ =150.7, 149.1, 137.6, 133.3, 132.5, 130.3, 126.1, 124.4, 118.8, 116.1; MS (EI) m/z (%) 260 (M^+ , 100), 179 (100), 152 (70), 125 (23).

2-(4-chlorophenyl)isonicotinonitrile (5i-C2), 3-(4-chlorophenyl)isonicotinonitrile (5i-C3).




EtOAc/*n*-hexane (1:10); C2: pale yellow solid (30.5mg, 28.4%); ^1H NMR (400 MHz, CDCl_3) δ =8.85 (dd, J = 4.9, 0.5 Hz, 1H), 7.94 (t, J = 9.7 Hz, 3H), 7.50-7.46 (m, 3H); ^{13}C NMR (100 MHz, CDCl_3) δ =157.5, 150.7, 136.6, 135.7, 129.3, 128.2, 123.4, 121.8, 121.4, 116.6; MS (EI) m/z (%) 214 (M^+ , 100), 179 (93), 152 (44); C3: pale yellow solid (29.7mg, 27.7%); ^1H NMR (400 MHz, CDCl_3) δ =8.84 (s, 1H), 8.77 (d, J = 5.0 Hz, 1H), 7.63 (d, J = 5.0 Hz, 1H), 7.54-7.51 (m, 4H); ^{13}C NMR (100 MHz, CDCl_3) δ =150.7, 149.1, 137.6, 136.1, 132.8, 130.1, 129.5, 126.1, 118.8, 116.1; MS (EI) m/z (%) 214 (M^+ , 100), 179 (84), 152 (38).

2-(2-chlorophenyl)isonicotinonitrile (5j-C2), 3-(2-chlorophenyl)isonicotinonitrile (5j-C3).




EtOAc/*n*-hexane (1:10); C2: pale yellow solid (46.7mg, 43.5%); ^1H NMR (400 MHz, CDCl_3) δ =8.91 (dd, J = 5.0, 0.5 Hz, 1H), 7.94 (s, 1H), 7.62-7.60 (m, 1H), 7.54-7.51 (m, 2H), 7.42-7.40 (m, 2H); ^{13}C NMR (100 MHz, CDCl_3) δ =158.2, 150.6, 137.2, 132.1, 131.5, 130.7, 130.4, 127.3, 126.6, 123.7, 120.4, 116.5; MS (EI) m/z (%) 214 (M^+ , 100), 179 (95), 152 (56), 125 (20); C3: pale yellow solid (37.4mg, 17.4%); ^1H NMR (400 MHz, CDCl_3) δ =8.82 (t, J = 2.5 Hz, 2H), 7.67-7.66 (m, 1H), 7.58 (dd, J = 7.9, 1.6 Hz, 1H), 7.49-7.41 (m, 2H), 7.37 (dd, J = 7.2, 2.2 Hz, 2H); ^{13}C NMR (100 MHz, CDCl_3) δ =151.2, 149.0, 137.4, 136.9, 133.2 (d, J = 4.4 Hz), 132.4, 131.2 (d, J = 9.8 Hz), 127.3, 125.6, 130.3, 121.3, 115.4; MS (EI) m/z (%) 214 (M^+ , 93), 179 (100), 152 (61), 125 (12).

2-(3-chlorophenyl)isonicotinonitrile (5k-C2), 3-(3-chlorophenyl)isonicotinonitrile (5k-C3).




EtOAc/*n*-hexane (1:10); C2: pale yellow solid (52.9mg, 49.3%); ¹H NMR (400 MHz, CDCl₃) δ=8.87 (dd, *J* = 5.0, 0.6 Hz, 1H), 8.04 (s, 1H), 7.93 (s, 1H), 7.88-7.785 (m, 1H), 7.49 (dd, *J* = 5.0, 1.3 Hz, 1H), 7.46-7.45 (m, 2H); ¹³C NMR (100 MHz, CDCl₃) δ=157.3, 150.8, 139.0, 135.3, 130.3, 130.2, 127.2, 125.0, 123.8, 122.1, 121.5, 116.5; MS (EI) *m/z* (%) 214 (M⁺,100), 179 (72), 145 (10); C3: pale yellow solid (30.8mg, 28.7%); ¹H NMR (400 MHz, CDCl₃) δ=8.85(s, 1H), 8.79 (d, *J* = 5.0 Hz, 1H), 7.65 (d, *J* = 5.0 Hz, 1H), 7.56 (d, *J* = 1.4 Hz, 1H), 7.51-7.48 (m, 3H); ¹³C NMR (100 MHz, CDCl₃) δ=150.8, 149.3, 137.3, 136.2, 135.2, 130.4, 129.7, 128.8, 127.1, 126.1, 119.0, 115.9; MS (EI) *m/z* (%) 214 (M⁺,100), 179 (72), 152 (24).

2-(naphthalen-2-yl)isonicotinonitrile (5l-C2), 3-(naphthalen-2-yl)isonicotinonitrile (5l-C3),




EtOAc/*n*-hexane (1:10); C2: pale yellow solid (28.9mg, 25.1%); ¹H NMR (400 MHz, CDCl₃) δ=8.90 (d, *J* = 4.9, 1H), 8.50 (s, 1H), 8.11 (dd, *J* = 8.6, 1.7 Hz, 1H), 8.09 (s, 1H), 7.99-7.96 (m, 2H), 7.89 (t, *J* = 4.3, 1H), 7.56-7.54 (m, 2H), 7.47(dd, *J* = 4.9, 1.2 Hz, 2H); ¹³C NMR (100 MHz, CDCl₃) δ=158.7, 150.7, 134.5, 134.1, 133.3, 128.9 (2C), 127.8, 127.3, 127.0, 126.7, 123.9, 123.1, 122.3, 121.3, 116.8; MS (EI) *m/z* (%) 230 (M⁺,100), 201 (10), 175 (8); C3: pale yellow solid (26.4mg, 22.9%); ¹H NMR (400 MHz, CDCl₃) δ=8.97(s, 1H), 8.78 (d, *J* = 4.6 Hz, 1H), 8.07 (s, 1H), 8.02 (d, *J* = 8.4 Hz, 1H), 7.96-7.91 (m, 2H), 7.69-7.65 (m, 2H), 7.59-7.57 (m, 2H); ¹³C NMR (100 MHz, CDCl₃) δ=151.2, 148.7, 138.8, 133.4, 133.2, 131.8, 129.1, 128.7, 128.5, 127.8, 127.4, 127.0, 126.2, 125.8, 119.1, 116.4; MS (EI) *m/z* (%) 230 (M⁺,100), 201 (10), 175 (6).

4-trifluoromethyl -2-phenylpyridine (5m).




EtOAc/*n*-hexane (1:10); colorless oil (84.6mg, 75.9%); ¹H NMR (400 MHz, CDCl₃) δ=8.84 (d, *J* = 5.0 Hz, 1H), 8.02 (dd, *J* = 8.3, 1.6 Hz, 2H), 7.91 (s, 1H), 7.51-7.45 (m, 3H), 7.42 (d, *J* = 5.2 Hz, 1H); ¹³C NMR (100 MHz, CDCl₃) δ=158.8, 150.6, 139.0, 138.0, 129.8, 129.0, 127.0, 117.5 (q, *J* = 3.2 Hz), 116.0 (d, *J* = 3.6 Hz); MS (EI) *m/z* (%) 223 (M⁺,100), 204 (50), 154 (90), 127(45).

ethyl 2-phenylisonicotinate (5n).




EtOAc/*n*-hexane (1:10); pale yellow oil (68.8mg, 60.6%); The spectroscopic data for these compounds were identical to those reported in the literature: Tetrahedron Letters, 2008, 49, 4349.

4-Acetyl -2-phenylpyridine (5o-C2), 4-Acetyl -3-phenylpyridine (5o-C3).




EtOAc/*n*-hexane (1:10); C2: white solid (60.6mg, 61.5%); ¹H NMR (400 MHz, CDCl₃) δ=8.87 (d, *J* = 5.0 Hz, 1H), 8.17 (s, 1H), 8.06-8.04 (m, 2H), 7.65 (dd, *J* = 5.0, 1.4 Hz, 1H), 7.53-7.45 (m, 3H), 2.68 (s, 3H); ¹³C NMR (100 MHz, CDCl₃) δ=197.5, 158.9, 150.1, 150.8, 143.7, 138.6, 129.5, 128.9, 127.0, 119.7, 118.0, 26.8; MS (EI) *m/z* (%) 197 (M⁺,100), 182 (100), 154 (96), 127(80); C3: trace.

3-Acetyl -2-phenylpyridine (5p-C2), 3-Acetyl -4-phenylpyridine(5p-C4), 3-Acetyl -6-phenylpyridine (5p-C6).



EtOAc/*n*-hexane (1:10); C6: white solid (26.4mg, 26.8%); ¹H NMR (400 MHz, CDCl₃) δ=9.24 (d, *J* = 2.0 Hz, 1H), 8.30 (dd, *J* = 8.3, 2.3 Hz, 1H), 8.07 (dd, *J* = 8.2, 1.8 Hz, 2H), 7.85 (dd, *J* = 8.3, 0.6 Hz, 1H), 7.54-7.48 (m, 3H), 2.67(s, 3H); ¹³C NMR (100 MHz, CDCl₃) δ=196.5, 161.0, 150.1, 138.2, 136.4, 130.6, 130.1, 129.0, 127.4, 120.2, 26.8; MS (EI) *m/z* (%) 197 (M⁺,100), 182 (100), 154 (100), 127(90); C2 and C6 (3:1): light yellow oil (37.0mg, 37.5%); ¹H NMR (400 MHz, CDCl₃) δ=9.24 (d, *J* = 1.8 Hz, 0.3H), 8.77 (dd, *J* = 4.8, 1.7 Hz, 1H), 8.30 (dd, *J* = 8.4, 2.3 Hz, 0.3H), 8.07 (dd, *J* = 8.2, 1.8 Hz, 0.6H), 7.87 (dd, *J* = 7.7, 1.7 Hz, 1H), 7.74-7.71 (m, 1H), 7.59-7.56 (m, 2H), 7.54-7.52 (m, 1.3H), 7.49-7.47 (m, 2H), 7.37-7.34 (m, 1H), 2.67(s, 1H), 2.07(s, 3H); ¹³C NMR (100 MHz, CDCl₃) δ=203.7, 199.1, 157.2, 150.9, 150.2, 139.7, 138.2, 136.4, 136.2, 132.3, 130.9, 130.1, 129.4, 129.1, 129.0, 128.8 (2C), 127.4, 121.9, 120.2, 30.3, 26.8; MS (EI) *m/z* (%) 197 (M⁺,65), 182 (100), 154 (47), 127(35); C4:trace.


3-fluoro -2-phenylpyridine (5q-C2), 3-fluoro -4-phenylpyridine(5q-C4), 3-fluoro -6-phenylpyridine (5q-C6).



EtOAc/*n*-hexane (1:10); C2: pale yellow solid (18.8mg, 21.7%); ¹H NMR (400 MHz, CDCl₃) δ=8.54 (d, *J* = 2.6Hz, 1H), 8.47 (d, *J* = 4.9Hz, 1H), 7.62-7.60 (m, 2H), 7.52-7.46 (m, 3H), 7.42-7.39 (m, 1H); ¹³C NMR (100 MHz, CDCl₃) δ=157.9, 155.4, 146.0 (d, *J* = 5.2Hz), 139.1 (d, *J* = 25.7Hz), 136.1 (d, *J* = 10.7Hz), 132.9, 129.3, 128.8 (d, *J* = 2.4Hz), 124.2; MS (EI) *m/z*


(%) 173 (M^+ ,100), 146 (26), 125 (13); C4 and C6 : light yellow oil (50.2mg, 58.0%); 1H NMR (400 MHz, $CDCl_3$) δ =8.53-8.51 (m, 2H), 7.98-7.95 (m, 4H), 7.51-7.42 (m, 8H), 7.28-7.24 (m, 2H); ^{13}C NMR (100 MHz, $CDCl_3$) δ =158.8, 156.2, 146.3, 146.2, 145.4 (d, J = 5.3Hz), 135.3 (d, J = 5.3Hz), 129.2, 128.8 (d, J = 5.5Hz), 128.5, 128.4, 127.3, 124.2, 124.0, 123.8, 123.5, 123.4; MS (EI) m/z (%) 173 (M^+ ,100), 154 (16), 140 (24), 125 (14); 173 (M^+ ,78), 154 (20), 146 (27), 125 (15).

3-chloro -2-phenylpyridine (5r-C2), 3-chloro -4-phenylpyridine(5r-C4), 3-chloro -6-phenylpyridine (5r-C6).




EtOAc/*n*-hexane (1:10); C2: light yellow oil (24.4mg, 25.7%); 1H NMR (400 MHz, $CDCl_3$) δ =8.60 (dd, J = 4.6, 1.4 Hz, 1H), 7.80 (dd, J = 4.6, 1.4 Hz, 1H), 7.74-7.72 (m, 2H), 7.50-7.43 (m, 3H), 7.24-7.21 (m, 1H); ^{13}C NMR (100 MHz, $CDCl_3$) δ =156.6, 147.6, 138.2, 138.1, 130.2, 129.3, 128.8, 128.1, 123.1; MS (EI) m/z (%) 189 (M^+ ,95), 154 (100), 127 (70), 77 (38); C6 : pale yellow solid (36.5mg, 38.5%); 1H NMR (400 MHz, $CDCl_3$) δ =8.57 (d, J = 2.3Hz, 1H), 7.89 (dd, J = 8.6, 1.6 Hz, 2H), 7.67-7.60 (m, 2H), 7.43-7.36 (m, 3H); ^{13}C NMR (100 MHz, $CDCl_3$) δ =154.6, 147.5, 137.2, 135.4, 128.3, 129.6, 127.8, 125.8, 120.1; MS (EI) m/z (%) 189 (M^+ ,100), 154 (63), 127 (22), 77 (15). C4: trace.

3-bromo -2-phenylpyridine (5s-C2), 3-bromo -4-phenylpyridine(5s-C4), 3-chloro -6-phenylpyridine (5s-C6).




EtOAc/*n*-hexane (1:10); C6: pale yellow solid (12.5mg, 10.7%); 1H NMR (400 MHz, $CDCl_3$) δ =8.67 (s, 1H), 7.89 (d, J = 7.8Hz, 2H), 7.80 (dd, J = 8.5, 2.0 Hz, 1H), 7.56 (d, J = 8.4 Hz, 1H), 7.43-7.36 (m, 3H); ^{13}C NMR (100 MHz, $CDCl_3$) δ =155.2, 149.7, 138.3, 137.2, 128.3, 127.9, 125.7, 120.6, 118.3; MS (EI) m/z (%) 233 (M^+ ,100), 154 (57), 127 (43), 77 (28); C2 and C4 : light yellow oil (55.3mg, 47.2%); 1H NMR (400 MHz, $CDCl_3$) δ =8.82 (s, 1H), 8.62 (dd, J = 4.6, 1.1 Hz, 1H), 8.54 (d, J = 4.9Hz, 1H), 7.99 (dd, J = 8.0, 1.1 Hz, 1H), 7.68 (dd, J = 7.9, 1.7 Hz, 2H), 7.49-7.43 (m, 8H), 7.26 (d, J = 2.3 Hz, 1H), 7.16-7.12 (m, 1H); ^{13}C NMR (100 MHz, $CDCl_3$) δ =158.2, 152.5, 149.7, 148.3, 148.1, 141.3, 139.6, 138.2, 129.3, 128.8, 128.7, 128.4, 128.0, 125.7, 123.3, 120.9, 119.8; MS (EI) m/z (%) 233 (M^+ ,100), 154 (85), 127 (98), 77 (39); 233 (M^+ ,78), 154 (100), 127 (90), 77 (51).

4-(tert-butyl)-2-phenylpyridine (5t)




EtOAc/*n*-hexane (1:10); light yellow oil (72.0mg, 68.2%); The spectroscopic data for these compounds were identical to those reported in the literature: J. Am. Chem. Soc. 2010, 132, 13194

4-methoxy-2-phenylpyridine (5u)




EtOAc/n-hexane (1:10); white solid (32.9mg, 35.6%); The spectroscopic data for these compounds were identical to those reported in the literature: Chem. Commun., 2010, 46, 3384.

2-phenylpyrazine (5v).




EtOAc/n-hexane (1:10); pale yellow solid (41.1mg, 52.6%); ¹H NMR (400 MHz, CDCl₃) d=9.04(d, *J* = 1.5 Hz, 1H), 8.65-8.64 (m, 1H), 8.52 (d, *J* = 2.5 Hz, 1H), 8.04-8.01 (m, 2H) 7.55-7.47; (m, 3H) ¹³C NMR (100 MHz, CDCl₃) d=152.9, 144.2, 142.9, 142.3, 136.4, 129.9, 129.1, 127.0; MS (EI) *m/z* (%) 156 (M⁺,100), 129 (12), 103(54), 76(10).

2-phenylpyrimidine (5w-C2), 4-phenylpyrimidine (5w-C4).




EtOAc/n-hexane (1:10); C4: white solid (72.9mg, 93.4%); ¹H NMR (400 MHz, CDCl₃) d=9.28(d, *J* = 1.1 Hz, 1H), 8.77 (d, *J* = 5.4 Hz, 1H), 8.11-8.08 (m, 2H), 7.73 (dd, *J* = 5.4, 1.4 Hz, 1H); 7.55-7.47 (m, 3H) ¹³C NMR (100 MHz, CDCl₃) d=163.9, 159.1, 157.5, 136.5, 131.1, 129.1, 127.1, 117.0; MS (EI) *m/z* (%) 156 (M⁺,100), 129 (12), 103(54), 76(10); C2: trace.

2-phenylquinoline (5x -C2), 4-phenylquinoline (5x -C4).



EtOAc/n-hexane (1:10); C2: pale yellow solid (29.3mg, 28.6%); The spectroscopic data for these compounds were identical to those reported in the literature: Chem. Commun., 2011, 47, 12840. C4: pale yellow oil (21.7mg, 21.1%); The spectroscopic data for these compounds were identical to those reported in the literature: Eur. J. Org. Chem. 2006, 1917.


2-phenylquinoxaline (5y).



EtOAc/n-hexane (1:10); pale yellow solid (52.1mg, 50.5%); ¹H NMR (400 MHz, CDCl₃) d=9.34(s, 1H), 8.22-8.12 (m, 4H), 7.82-7.74 (m, 2H), 7.60-7.53 (m, 3H); ¹³C NMR (100 MHz,

CDCl₃) δ =151.9, 143.4, 142.3, 141.6, 136.8, 130.3, 130.2, 129.7, 129.6, 129.2, 129.1, 127.6;
MS (EI) m/z (%) 206 (M^+ ,100), 179 (100), 152(30), 103(50), 76(66), 50(35).



3, 6-dichloro-4-phenylpyridazine (5z).




EtOAc/*n*-hexane (1:10); pale yellow solid (19.5mg, 17.3%); ¹H NMR (400 MHz, CDCl₃) δ =7.55-7.50 (m, 6H); ¹³C NMR (100 MHz, CDCl₃) δ =156.0, 154.9, 142.8, 133.2, 130.4, 129.6, 129.0, 128.9; MS (EI) m/z (%) 225(M^+ ,84), 224 (100), 196(55), 161(53), 136(75), 126(70).

Copies of product ¹H NMR and ¹³C NMR

2-Phenyl-1, 4-benzoquinone (3a)



2-(4-Methylphenyl)-1, 4-benzoquinone (3b)




Current Data Parameters
NAME WJ-1262
EXPNO 1
PROCNO 1

F2 - Acquisition Parameters
Date_ 20120228
Time 18.38
INSTRUM spect
PROBHD 5 mm PABBO BB/
PULPROG zg30
TD 65536
SOLVENT CDCl3
NS 16
DS 2
SWH 8223.685 Hz
FIDRES 0.125463 Hz
AQ 3.9846387 sec
RG 177.75
DW 60.800 usec
DE 8.00 usec
TE 294.2 K
D1 1.00000000 sec
TDO 1

===== CHANNEL f1 =====
NUC1 1H
P1 12.60 usec
PLW1 15.84899999 W
SFO1 400.1632013 MHz

F2 - Processing parameters
SI 65536
SF 400.1600086 MHz
WDW EM
SSB 0
LB 0.30 Hz
GB 0
PC 1.00





NAME 2012-03-21 wangjian-1262
EXPNO 1
PROCNO 1
Date_ 20120322
Time 3.14
INSTRUM spect
PROBHD 5 mm PABBO BB-
PULPROG zgpg30
TD 65536
SOLVENT CDCl3
NS 256
DS 4
SWH 24038.461 Hz
FIDRES 0.366798 Hz
AQ 1.3631988 sec
RG 2050
DW 20.800 usec
DE 6.50 usec
TE 297.5 K
D1 2.00000000 sec
d11 0.03000000 sec
DELTA 1.89999999 sec
TDO 1



===== CHANNEL f1 =====
NUC1 13C
P1 19.40 usec
PL1 -1.00 dB
SFO1 100.6226299 MHz

===== CHANNEL f2 =====
CPDPRG2 waltz16
NUC2 1H
PCPD2 60.00 usec
PL12 11.09 dB
PL13 13.05 dB
PL2 -2.00 dB
SFO2 400.1316005 MHz
SI 32768
SF 100.6127690 MHz
WDW EM
SSB 0
LB 1.00 Hz
GB 0
PC 1.40



2-(3-Methylphenyl)-1, 4-benzoquinone (3c)





2-(2-Methylphenyl)-1, 4-benzoquinone (3d)





2-(4-Methoxyphenyl)-1, 4-benzoquinone (3e)





2-(4-*tert*-Butylphenyl)-1, 4-benzoquinone (3f)





2-(4-Fluorophenyl)-1, 4-benzoquinone (3g)





2-(4-Bromophenyl)-1, 4-benzoquinone (3h)





2-(4-Chlorophenyl)-1, 4-benzoquinone (3i)





2-(3-Chlorophenyl)-1, 4-benzoquinone (3j)





2-(2-Chlorophenyl)-1, 4-benzoquinone (3k)







2- (naphthalen-2-yl) -1,4-benzoquinone (3l)





2,6-Dimethyl-3-phenyl-1,4-benzoquinone (3n)





2,6-Dimethoxy-3-(4-methylphenyl)-1,4-benzoquinone (3o)





2,3-Dimethoxy-5-methyl-6-phenyl-1,4-benzoquinone (3q)





2,5-Dichloro-3-phenyl-1,4-benzoquinone (3r)






2-phenyl-1,4-naphthoquinone (3s)





2-phenylisonicotinonitrile (5a-C2)





3-phenylisonicotinonitrile (5a-C3)





2-(*o*-tolyl)isonicotinonitrile (5b-C2)





3-(*o*-tolyl)isonicotinonitrile (5b-C3)





2-(*m*-tolyl)isonicotinonitrile (5c-C2)





3-(*m*-tolyl)isonicotinonitrile (5c-C3)





2-(*p*-tolyl)isonicotinonitrile (5d-C2)





3-(*p*-tolyl)isonicotinonitrile (5d-C3)





2-(4-methoxyphenyl)isonicotinonitrile (5e-C2)





3-(4-methoxyphenyl)isonicotinonitrile (5e-C3)




2-(4-*tert*-butylphenyl)isonicotinonitrile (5f-C2)




3-(4-*tert*-butylphenyl)isonicotinonitrile (5f-C3)



2-(4-fluorophenyl)isonicotinonitrile (5g-C2)





NAME 2012-04-27 wangjian-1379-C2
EXPRO 1
PROCNO 1
Date_ 20120428
Time 1.16
INSTRUM spect
PROBHD 5 mm F400 BB-
PULPROG zgpg30
TD 65536
SOLVENT CDCl3
NS 16
DS 0
SWH 8223.685 Hz
FIDRES 0.125483 Hz
AQ 3.9846387 sec
RG 486
DW 60.800 usec
DE 6.50 usec
TE 295.1 K
D1 1.00000000 sec
TDO 1
----- CHANNEL f1 -----
NUC1 1H
P1 13.30 usec
PL1 -2.00 dB
SFO1 400.1324710 MHz
SI 32768
SF 400.1300087 MHz
WDW EM
SSB 0
LB 0.30 Hz
GB 0
PC 1.00




NAME 2012-04-27 wangjian-1379-C2
EXPRO 2
PROCNO 1
Date_ 20120428
Time 1.34
INSTRUM spect
PROBHD 5 mm F400 BB-
PULPROG zgpg30
TD 65536
SOLVENT CDCl3
NS 16
DS 0
SWH 24038.461 Hz
FIDRES 0.366798 Hz
AQ 1.3631988 sec
RG 812
DW 20.800 usec
DE 6.50 usec
TE 295.2 K
D1 2.00000000 sec
d11 0.03000000 sec
DELTA 1.89999998 sec
TDO 1
----- CHANNEL f1 -----
NUC1 13C
P1 19.40 usec
PL1 -1.00 dB
SFO1 100.6228298 MHz
----- CHANNEL f2 -----
CPDPRG2 waltz16
NUC2 1H
PCPD2 60.00 usec
PL12 11.09 dB
PL13 13.05 dB
PL2 -2.00 dB
SFO2 400.1316003 MHz
SI 32768
SF 100.6127690 MHz
WDW EM
SSB 0
LB 1.00 Hz
GB 0
PC 1.40



3-(4-fluorophenyl)isonicotinonitrile (5g-C3)






2-(4-bromophenyl)isonicotinonitrile (5h-C2)





3-(4-bromophenyl)isonicotinonitrile (5h-C3)





2-(4-chlorophenyl)isonicotinonitrile (5i-C2)





3-(4-chlorophenyl)isonicotinonitrile (5i-C3)





2-(2-chlorophenyl)isonicotinonitrile (5j-C2)





3-(2-chlorophenyl)isonicotinonitrile (5j-C3)





2-(3-chlorophenyl)isonicotinonitrile (5k-C2)





3-(3-chlorophenyl)isonicotinonitrile (5k-C3)







2-(naphthalen-2-yl)isonicotinonitrile (5l-C2)





3-(naphthalen-2-yl)isonicotinonitrile (5l-C3)





4-trifluoromethyl -2-phenylpyridine (5m)





4-Acetyl -2-phenylpyridine (50-C2)





3-Acetyl -2-phenylpyridine (5p-C2) and 3-Acetyl-6-phenylpyridine (5p-C6)





3-Acetyl-6-phenylpyridine (5p-C6)





3-fluoro -2-phenylpyridine (5q-C2)





3-fluoro -4-phenylpyridine(5q-C4) and 3-fluoro-6-phenylpyridine (5q-C6)





3-chloro -2-phenylpyridine (5r-C2)





3-chloro-6-phenylpyridine (5r-C6)





3-bromo -2-phenylpyridine (5s-C2) and 3-bromo -4-phenylpyridine(5s-C4)





3-bromo-6-phenylpyridine (5s-C6)





2-phenylpyrazine (5v)



4-phenylpyrimidine (5w-C4)



2-phenylquinoxaline (5y)



3, 6-dichloro-4-phenylpyridazine (5z)

